GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a US based full-service contract research organisation (CRO), have signed a strategic Memorandum of Understanding (MoU) pursuant to which they intend to explore ways to strengthen their presence in the global clinical trial market.
In signing the MoU, GCCL and Frontage intend to consider opportunities to leverage the complementary services and networks of both companies to enhance competitiveness, particularly in the United States and Asia-Pacific (APAC) regions, while driving mutual growth.
In particular, during the signing ceremony, the two companies reaffirmed their commitment to collaboration and discussed opportunities for cooperation including joint clinical trial services in the US and APAC regions, co-marketing and project support initiatives, development of new business opportunities, and additional initiatives.
In addition, GCCL and Frontage will combine their respective regional expertise and global networks to collaborate in executing clinical trial projects while increasing efficiency and differentiation of services for clients worldwide. In doing so, GCCL would expect to further strengthen its global capabilities, while Frontage would look to bolster its clinical trial support system in the APAC region.
